Citation

de Abreu MS, Giacomini ACVV, Genario R, dos Santos BE, da Rosa LG, Demin KA, Wappler-Guzzetta E, Kalueff AV. Pharmacol. Res. 2019; 141: 602-608.

Affiliation

Institute of Experimental Medicine, Almazov National Medical Research Center, Ministry of Healthcare of Russian Federation, St. Petersburg, Russia; School of Pharmacy, Southwest University, Chongqing, China; Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg, Russia; Research Institute of Physiology and Basic Medicine, Novosibirsk, Russia; Ural Federal University, Ekaterinburg, Russia; Granov's Russian Scientific Research Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russian Federation, Pesochny, Russia; Almazov National Medical Research Center, Ministry of Healthcare of Russian Federation, St. Petersburg, Russia; ZENEREI Research Center, Slidell, LA, USA. Electronic address: avkalueff@gmail.com.

Copyright

(Copyright © 2019, Elsevier Publishing)

DOI

10.1016/j.phrs.2019.01.044

PMID

30708051

Abstract

The zebrafish (Danio rerio) is increasingly utilized as a powerful new model organism in neurobehavioral research. Aggression is a common symptom of many CNS disorders, has some genetic deterinants and can be modulated pharmacologically in humans and animal model species. Mounting evidence suggests zebrafish as a useful tool to study neurobiology of aggression, and its pharmacological and genetic regulation. Here, we discuss mechanisms of zebrafish aggression and their pharmacological, pharmacogenetic and pharmacogenomic models, as well as recent developments and existing challenges in this field. We also emphasize the growing utility of zebrafish models in translational neuropharmacological research of aggression, fostering future discoveries of potential therapeutic agents for aggressive behavior.

Copyright © 2019. Published by Elsevier Ltd.

Language: en

Keywords

CNS; aggression; animal models; epigenetics; pharmacological modulation